title: Respiratory infection in noncystic fibrosis bronchiectasis.
abstract: OBJECTIVE
  We highlight some of the main developments in the investigation and management of bronchiectasis, a condition causing susceptibility to airway infections and in more severe cases chronic bronchial suppuration.
  
  
  RESULTS
  Chronic infection with Pseudomonas aeruginosa and poor lung function adversely influence long-term prognosis. Investigation of the underlying cause of bronchiectasis leads to additional therapy in a higher proportion of patients than previously thought. Based on current data, inhaled corticosteroid cannot be recommended for routine use in patients with bronchiectasis. Nontuberculous mycobacterial infections have been associated with both aspergillus and gastrooesophageal reflux. There is new evidence supporting the practice of regular chest physiotherapy.
  
  
  CONCLUSIONS
  Despite some improvement in the evidence-based guide to management in noncystic fibrosis bronchiectasis, there remains a serious lack of randomized controlled trials directing therapy.
authors.affiliation: Host Defence Unit, Royal Brompton Hospital, London, UK.
authors.forename: Zaid
authors.initials: Z
authors.lastname: Zoumot
authors.forename: Robert
authors.initials: R
authors.lastname: Wilson
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001987:Bronchiectasis / Q000150:complications*; D006801:Humans; D026741:Physical Therapy Modalities; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D055732:Pulmonary Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents